바이오뱅크 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 바이오 샘플 유형별, 바이오뱅크 유형별, 서비스별, 용도별, 지역별, 부문별 예측(2026-2033년)

Biobanks Market Summary

The global biobanks market size was estimated at USD 86.82 billion in 2025 and is anticipated to reach USD 160.54 billion by 2033, growing at a CAGR of 8.11% from 2026 to 2033. High investments in the R&D of advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, are some of the driving factors.

Global Biobanks Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biobanks market report based on product & service, biospecimen type, biobank type, application, and region:

• Product & Services Outlook (Revenue, USD Million, 2021 - 2033)
• Product
  • Biobanking Equipment
  • Temperature Control Systems
  • Freezers & Refrigerators
  • Cryogenic Storage Systems
  • Thawing Equipment
  • Incubators & Centrifuges
  • Alarms & Monitoring Systems
  • Accessories & Other Equipment
  • Biobanking Consumables
  • Laboratory Information Management Systems
• Services
  • Biobanking & Repository
  • Lab processing
  • Qualification/ Validation
  • Cold Chain Logistics
  • Other Services
• Biospecimen Type Outlook (Revenue, USD Million, 2021 - 2033)
• Human Tissues
• Human Organs
• Stem Cells
  • Adult Stem Cells
  • Embryonic Stem Cells
  • IPS Cells
  • Other Stem Cells
• Other Biospecimens
• Biobank Type Outlook (Revenue, USD Million, 2021 - 2033)
• Physical/Real Biobanks
  • Tissue Biobanks
  • Population-Based Biobanks
  • Genetic (DNA/RNA)
  • Disease-Based Biobanks
• Virtual Biobanks
• Application Type Outlook (Revenue, USD Million, 2021 - 2033)
• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics
• Other Applications
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Biospecimen Type
  • 1.2.3. Biobank Type
  • 1.2.4. Application
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biobanks Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increased focus on precision medicine and genetic testing
    • 3.2.1.2. Changes in biobanking operations
    • 3.2.1.3. Increase in the number of clinical trials globally
    • 3.2.1.4. Growing industry and research collaborations
    • 3.2.1.5. Technology advancement and automation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges in sharing biobanking data & limited access to biospecimens
    • 3.2.2.2. Sustainability challenges for biobanks
    • 3.2.2.3. Other challenges in biobanking specimens for research
• 3.3. Biobanks Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Biobanks Market: Product & Services Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Product & Services Market Share, 2025 & 2033
• 4.3. Product
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 4.4.1. Biobanking Equipment
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.2. Temperature Control Systems
      • 4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2.2. Freezers & Refrigerators
        • 4.4.1.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2.3. Cryogenic Storage Systems
      • 4.4.1.2.4. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2.5. Thawing Equipment
      • 4.4.1.2.6. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.3. Incubators & Centrifuges
      • 4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.4. Alarms & Monitoring Systems
      • 4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.5. Accessories & Other Equipment
      • 4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Biobanking Consumables
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Laboratory Information Management Systems
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Services
• 4.6. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.6.1. Biobanking & repository
    • 4.6.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.2. Lab processing
    • 4.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.3. Qualification/ Validation
    • 4.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.4. Cold Chain Logistics
    • 4.6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.5. Other Services
    • 4.6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Biobanks Market: Biospecimen Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Biospecimen Type Market Share, 2025 & 2033
• 5.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 5.3.1. Human Tissues
    • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Human Organs
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.3. Stem Cells
    • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3.2. Adult Stem Cells
      • 5.3.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3.3. Embryonic Stem Cells
      • 5.3.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3.4. IPS Cells
      • 5.3.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3.5. Other Stem Cells
      • 5.3.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.4. Other biospecimens
    • 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Biobanks Market: Biobank Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Biobank Type Market Share, 2025 & 2033
• 6.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 6.3.1. Physical/Real biobanks
    • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.1.2. Tissue Biobanks
      • 6.3.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.1.3. Population-based biobanks
      • 6.3.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.1.4. Genetic (DNA/RNA)
      • 6.3.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.1.5. Disease-Based biobanks
      • 6.3.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Virtual biobanks
    • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Biobanks Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Application Market Share, 2025 & 2033
• 7.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 7.3.1. Therapeutics
    • 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Drug discovery & clinical research
    • 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Clinical Diagnostics
    • 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.4. Other Applications
    • 7.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Biobanks Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Norway
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2025
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Merck KGaA
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Qiagen
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Hamilton Company
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Tecan Trading AG
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Danaher Corporation
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Becton, Dickinson, and Company (BD)
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Biocision, LLC.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Taylor-Wharton
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Charles River Laboratories
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Lonza
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Stemcell Technologies
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Biovault Family
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Promocell Gmbh
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives
  • 9.4.15. Precision Cellular Storage Ltd. (Virgin Health Bank)
    • 9.4.15.1. Company overview
    • 9.4.15.2. Financial performance
    • 9.4.15.3. Product benchmarking
    • 9.4.15.4. Strategic initiatives